These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25653264)

  • 21. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
    Andres S; Merker M; Heyckendorf J; Kalsdorf B; Rumetshofer R; Indra A; Hofmann-Thiel S; Hoffmann H; Lange C; Niemann S; Maurer FP
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1564-1568. PubMed ID: 32053752
    [No Abstract]   [Full Text] [Related]  

  • 22. Should isoniazid and clofazimine be used to treat multidrug-resistant tuberculosis?
    Seung KJ
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):231-2; author reply 232. PubMed ID: 15732749
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.
    Cohen K; Maartens G
    Expert Opin Drug Saf; 2019 Oct; 18(10):875-882. PubMed ID: 31339384
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
    O'Donnell MR; Padayatchi N; Daftary A; Orrell C; Dooley KE; Rivet Amico K; Friedland G
    Lancet HIV; 2019 Mar; 6(3):e201-e204. PubMed ID: 30846058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 27. Tuberculosis treatment and drug regimens.
    Sotgiu G; Centis R; D'ambrosio L; Migliori GB
    Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017822. PubMed ID: 25573773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Nov; 48(5):1527-1529. PubMed ID: 27799401
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Wallis RS
    Eur Respir J; 2016 Nov; 48(5):1526-1527. PubMed ID: 27799400
    [No Abstract]   [Full Text] [Related]  

  • 30. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
    Cox V; Furin J
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs.
    Farooq HZ; Cirillo DM; Hillemann D; Wyllie D; van der Werf MJ; Ködmön C; Nikolayevskyy V
    Emerg Infect Dis; 2021 Mar; 27(3):985-987. PubMed ID: 33622487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities.
    Mingote LR; Namutamba D; Apina F; Barnabas N; Contreras C; Elnour T; Frick MW; Lee C; Seaworth B; Shelly D; Skipper N; dos Santos Filho ET
    Lancet; 2015 Jan; 385(9966):477-9. PubMed ID: 25018118
    [No Abstract]   [Full Text] [Related]  

  • 34. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S; Heuvelings CC; Janssen S; Grobusch MP
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
    J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Furin J; Diacon AH; Andries K
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):4-5. PubMed ID: 28157457
    [No Abstract]   [Full Text] [Related]  

  • 37. Clofazimine in the treatment of multidrug-resistant tuberculosis.
    Xu HB; Jiang RH; Xiao HP
    Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline in multidrug-resistant pulmonary tuberculosis GENESIS-SEFH drug evaluation report.
    Borrego Izquierdo Y; López Briz E; Márquez Saavedra E
    Farm Hosp; 2015 Jan; 39(1):1-5. PubMed ID: 25680429
    [No Abstract]   [Full Text] [Related]  

  • 39. Informed use of bedaquiline for tuberculosis.
    Lessem EM; Bernardo J; Reed C; Wegener DH
    Lancet; 2015 May; 385(9979):1724. PubMed ID: 25943933
    [No Abstract]   [Full Text] [Related]  

  • 40. Informed use of bedaquiline for tuberculosis.
    Furin J
    Lancet; 2015 May; 385(9979):1724-1725. PubMed ID: 25943932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.